vs

Side-by-side financial comparison of IMMUCELL CORP (ICCC) and Linde plc (LIN). Click either name above to swap in a different company.

Linde plc is the larger business by last-quarter revenue ($8.8M vs $5.5M, roughly 1.6× IMMUCELL CORP). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs -8.4%). Linde plc produced more free cash flow last quarter ($898.0K vs $-1.8M). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -96.7%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

ICCC vs LIN — Head-to-Head

Bigger by revenue
LIN
LIN
1.6× larger
LIN
$8.8M
$5.5M
ICCC
Growing faster (revenue YoY)
LIN
LIN
+16.7% gap
LIN
8.2%
-8.4%
ICCC
More free cash flow
LIN
LIN
$2.7M more FCF
LIN
$898.0K
$-1.8M
ICCC
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-96.7%
LIN

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
ICCC
ICCC
LIN
LIN
Revenue
$5.5M
$8.8M
Net Profit
$-139.7K
Gross Margin
42.9%
48.5%
Operating Margin
0.4%
27.8%
Net Margin
-2.5%
Revenue YoY
-8.4%
8.2%
Net Profit YoY
80.1%
EPS (diluted)
$-0.02
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICCC
ICCC
LIN
LIN
Q1 26
$8.8M
Q4 25
$8.8B
Q3 25
$5.5M
$8.6B
Q2 25
$6.4M
$8.5B
Q1 25
$8.1M
$8.1B
Q4 24
$7.8M
$8.3B
Q3 24
$6.0M
$8.4B
Q2 24
$5.5M
$8.3B
Net Profit
ICCC
ICCC
LIN
LIN
Q1 26
Q4 25
$1.5B
Q3 25
$-139.7K
$1.9B
Q2 25
$501.9K
$1.8B
Q1 25
$1.4M
$1.7B
Q4 24
$1.7B
Q3 24
$-701.7K
$1.6B
Q2 24
$-1.5M
$1.7B
Gross Margin
ICCC
ICCC
LIN
LIN
Q1 26
48.5%
Q4 25
Q3 25
42.9%
Q2 25
43.7%
Q1 25
41.6%
Q4 24
36.5%
Q3 24
26.3%
Q2 24
22.5%
Operating Margin
ICCC
ICCC
LIN
LIN
Q1 26
27.8%
Q4 25
23.0%
Q3 25
0.4%
27.5%
Q2 25
8.8%
27.7%
Q1 25
13.9%
26.9%
Q4 24
8.0%
27.4%
Q3 24
-9.6%
25.0%
Q2 24
-25.3%
26.4%
Net Margin
ICCC
ICCC
LIN
LIN
Q1 26
Q4 25
17.5%
Q3 25
-2.5%
22.4%
Q2 25
7.8%
20.8%
Q1 25
17.9%
20.6%
Q4 24
20.8%
Q3 24
-11.7%
18.5%
Q2 24
-28.0%
20.1%
EPS (diluted)
ICCC
ICCC
LIN
LIN
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$-0.02
$4.09
Q2 25
$0.06
$3.73
Q1 25
$0.16
$3.51
Q4 24
$0.09
$3.61
Q3 24
$-0.09
$3.22
Q2 24
$-0.20
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICCC
ICCC
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$3.9M
$4.0M
Total DebtLower is stronger
$9.5M
$24.7M
Stockholders' EquityBook value
$29.8M
$40.1M
Total Assets
$45.7M
$86.3M
Debt / EquityLower = less leverage
0.32×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICCC
ICCC
LIN
LIN
Q1 26
$4.0M
Q4 25
$5.1B
Q3 25
$3.9M
$4.5B
Q2 25
$4.8B
Q1 25
$5.3B
Q4 24
$3.8M
$4.8B
Q3 24
$5.2B
Q2 24
$1.3M
$4.6B
Total Debt
ICCC
ICCC
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$9.5M
$18.6B
Q2 25
$19.7B
Q1 25
$8.7M
$17.6B
Q4 24
$9.0M
$15.3B
Q3 24
$9.4M
$17.5B
Q2 24
$9.8M
$16.9B
Stockholders' Equity
ICCC
ICCC
LIN
LIN
Q1 26
$40.1M
Q4 25
$38.2B
Q3 25
$29.8M
$38.6B
Q2 25
$29.9M
$38.5B
Q1 25
$29.0M
$38.0B
Q4 24
$27.5M
$38.1B
Q3 24
$26.4M
$39.2B
Q2 24
$23.5M
$38.2B
Total Assets
ICCC
ICCC
LIN
LIN
Q1 26
$86.3M
Q4 25
$86.8B
Q3 25
$45.7M
$86.0B
Q2 25
$46.7M
$86.1B
Q1 25
$45.6M
$82.7B
Q4 24
$45.1M
$80.1B
Q3 24
$44.4M
$82.5B
Q2 24
$41.9M
$80.2B
Debt / Equity
ICCC
ICCC
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.32×
0.48×
Q2 25
0.51×
Q1 25
0.30×
0.46×
Q4 24
0.33×
0.40×
Q3 24
0.36×
0.45×
Q2 24
0.42×
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICCC
ICCC
LIN
LIN
Operating Cash FlowLast quarter
$-1.2M
Free Cash FlowOCF − Capex
$-1.8M
$898.0K
FCF MarginFCF / Revenue
-32.3%
10.2%
Capex IntensityCapex / Revenue
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$715.4K
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICCC
ICCC
LIN
LIN
Q1 26
Q4 25
$3.0B
Q3 25
$-1.2M
$2.9B
Q2 25
$1.6M
$2.2B
Q1 25
$1.6M
$2.2B
Q4 24
$-3.1K
$2.8B
Q3 24
$-639.3K
$2.7B
Q2 24
$581.8K
$1.9B
Free Cash Flow
ICCC
ICCC
LIN
LIN
Q1 26
$898.0K
Q4 25
$1.6B
Q3 25
$-1.8M
$1.7B
Q2 25
$1.4M
$954.0M
Q1 25
$1.2M
$891.0M
Q4 24
$-199.3K
$1.6B
Q3 24
$-727.7K
$1.7B
Q2 24
$471.0K
$796.0M
FCF Margin
ICCC
ICCC
LIN
LIN
Q1 26
10.2%
Q4 25
17.9%
Q3 25
-32.3%
19.4%
Q2 25
22.4%
11.2%
Q1 25
15.4%
11.0%
Q4 24
-2.6%
18.8%
Q3 24
-12.1%
19.9%
Q2 24
8.6%
9.6%
Capex Intensity
ICCC
ICCC
LIN
LIN
Q1 26
Q4 25
16.6%
Q3 25
10.8%
14.8%
Q2 25
2.4%
14.8%
Q1 25
4.1%
15.7%
Q4 24
2.5%
15.1%
Q3 24
1.5%
12.8%
Q2 24
2.0%
13.7%
Cash Conversion
ICCC
ICCC
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
3.19×
1.25×
Q1 25
1.09×
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons